Shares of Immunogen Inc. IMGN, +2.61% plummeted 48% toward a two-year low in premarket trade Friday, after the company said a phase 3 trial of its ovarian cancer treatment, mirvetuximab soravtansine, compared to chemotherapy, failed to meet its primary endpoint of progression free survival.
Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
UPDATE: Horizon Pharma stock soars 17% premarket on positive trial of eye disease treatment
Source: MarketWatch - 🏆 3. / 97 Read more »
Cancer patient's treatment leaves radiation contamination in crematoryRadioactivity was detected on the oven, vacuum filter and bone crusher of an Arizona crematory where a deceased man who'd received radiation therapy was incinerated, according to a new case report. Worse still, a radioactive compound unrelated to the dead man was detected in the urine of an employee there. In conclusion, drinking the radioactive ashes of a kemo patient DOES NOT give you super powers The tweet and the beadline contradict. I had radioactive treatment before and was told it exits the body in urine so you just flush twice after you pee. Oh, and you can't be near anyone under 20 yo cuz you'll mess up their bone growth. It was the 80s. Maybe things changed since then.
Source: CNN - 🏆 4. / 95 Read more »